HCAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Health Catalyst Inc (HCAT) does not present a strong buying opportunity for a beginner, long-term investor at this moment. The stock's technical indicators are mixed, with bearish moving averages and neutral RSI, while the MACD shows slight positive momentum. Insider selling has surged significantly, and analysts have lowered price targets, reflecting cautious sentiment. Additionally, the company's financial performance shows minimal revenue decline but remains unprofitable. With no strong positive catalysts or trading signals, it is advisable to hold off on investing in this stock currently.
The MACD histogram is positive at 0.0297, indicating slight upward momentum. However, the RSI is neutral at 63.804, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 1.94 and 2.042, while support levels are at 1.607 and 1.505. The stock is trading near resistance, suggesting limited immediate upside potential.
The MACD is showing positive momentum, and the stock has a 70% chance of gaining 2.2% in the next week and 3.49% in the next month.
Insiders are selling heavily, with an 869.22% increase in selling activity over the last month. Analysts have lowered price targets, and the company remains unprofitable despite slight improvements in net income and EPS. Additionally, there are no recent news or congress trading data to indicate strong interest or positive sentiment.
In Q3 2025, revenue slightly declined by 0.04% YoY to $76.32M. However, net income improved by 50.95% YoY to -$22.23M, and EPS increased by 33.33% YoY to -0.32. Gross margin also improved by 8.25% YoY to 34.51%. Despite these improvements, the company remains unprofitable.
Citi recently lowered the price target from $3.25 to $2.75, maintaining a Neutral rating. Analysts are cautiously optimistic for 2026 but acknowledge challenges in the health tech sector, with a significant portion of the group underperforming in 2025.
